drugset / Trial / NCT03397914

Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

NCT03397914

Phase 4 Completed 70 enrolled National Cancer Institute, Egypt
RandomizedParallel-groupOpen-labelTreatment

Summary

Prospective randomized study comparing different colistin dosing regimens in paediatric cancer patient with MDR gram-negative infection or sepsis

Timeline

Start
2017-01
Primary completion
2019-01
Completion
2019-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Colistimethate Unknown 1.25 mg/kg Intravenous
Subject Colistimethate Unknown 2.5 mg/kg Intravenous